News
BMS' radiopharma unit builds with $1.35bn Philochem deal
Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.
News
SpliceBio gathers $135m for eye disease gene therapies
Spain's SpliceBio has raised $135m in financing that will help it move a gene-editing therapy for Stargardt disease through clinical testing.
R&D
Transforming drug development with statistical methodologies
The product development lifecycle is long and challenging.
News
NewAmsterdam says lead drug may have Alzheimer's role
NewAmsterdam has said that an oral drug it is developing to lower cholesterol has shown early efficacy as a preventive therapy for Alzheimer's.
News
MSD moves ahead in race to bring oral PCSK9 drug to market
Armed with positive results in two phase 3 trials, MSD is poised to be the first to file for approval of an oral PCSK9 drug to lower cholesterol.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks